DGC810

**DGC810** is a preclinical dermatology drug discovery program from **Deargen** in its co-developed pipeline. Deargen's pipeline identifies DGC810 as a **Dermatology** candidate and places it in the **preclinical** stage, but the company does not publicly disclose the molecular target, mechanism of action, modality, dosage form, or route of administration on its pipeline page. The creation context indicates the program is partnered with **LG H&H**, suggesting DGC810 is a jointly developed dermatology asset rather than a marketed product.

Other names

DGC810-Deargen-DermatologyDGC-810-Deargen-DermatologyDGC 810-Deargen-Dermatology